Meeting
2022 ASCO Genitourinary Cancers Symposium
Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.
Authors
Elahe A. Mostaghel
VA Puget Sound Health Care System, Seattle, WA
Elahe A. Mostaghel , Xin Victoria Wang , Brett Marck , Alvin M. Matsumoto , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT00309985
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 146)
DOI
10.1200/JCO.2022.40.6_suppl.146
Abstract #
146
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo
Poster
2023 ASCO Genitourinary Cancers Symposium
Prognostic value of pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
First Author: Zhipeng Wang
Poster
2022 ASCO Quality Care Symposium
Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).
First Author: Neal D. Shore
Poster
2022 ASCO Genitourinary Cancers Symposium
Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.
First Author: Koshiro Nishimoto